✦ LIBER ✦

11 New response evaluation criteria in solid tumors: RECIST GUIDELINE VERSION 1.1

✍ Scribed by E.A. Eisenhauer; J. Verweij

Book ID: 119599781
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 45 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(09)70018-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

32 INVITED New response evaluation crite

32 INVITED New response evaluation criteria in solid tumors: revised RECIST guideline version 1.1

✍ E. Eisenhauer; P. Therasse; J. Bogaerts; L. Schwartz; D. Sargent; R. Ford; J. Da 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 56 KB

New response evaluation criteria in soli

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

✍ E.A. Eisenhauer; P. Therasse; J. Bogaerts; L.H. Schwartz; D. Sargent; R. Ford; J 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 761 KB

Response evaluation criteria in solid tu

Response evaluation criteria in solid tumors (RECIST): New guidelines

✍ Tsuchida, Yoshiaki ;Therasse, Patrick 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB

P-460 Inter-observer variability in tumo

P-460 Inter-observer variability in tumor response evaluation according to RECIST (Response Evaluation Criteria in Solid Tumors) guidelines

✍ Watanabe, Hirokazu; Kunitoh, Hideo; Yamamoto, Seiichiro; Kawasaki, Shin; Inoue, 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 180 KB

Outstanding problems with Response Evalu

Outstanding problems with Response Evaluation Criteria in Solid Tumors (RECIST) in breast cancer

✍ Morihiko Kimura; Takeshi Tominaga 📂 Article 📅 2002 🏛 Springer Japan 🌐 English ⚖ 721 KB

Comparison of tumor response by Response

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma

✍ Julien Edeline; Eveline Boucher; Yan Rolland; Elodie Vauléon; Marc Pracht; Chris 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 578 KB

## Abstract ## BACKGROUND: A significant improvement in overall survival (OS) was demonstrated in patients with advanced hepatocellular carcinoma (HCC) who received sorafenib (Sor) in the Sorafenib HCC Assessment Randomized Protocol (SHARP) study, in contrast to a response rate (RR) of 2% assessed